StockData
SPRCNasdaqPharmaceutical PreparationsFiscal year ends December 31

SciSparc Ltd.

Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 29, 2026
$1.40−0.30 (-17.65%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
0.1
Dividend yield
–

Ownership

Who owns SciSparc's shares

Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 1 sales
Net sold $4.62K

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
YA II PN, Ltd. ( )115,482–13G (passive)Mar 6, 2024

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Oz AdlerCEO and CFO11,0583.03%Jul 13, 2026
Adi Zuloff-ShaniChief Technology Officer5,5281.51%Jul 13, 2026
Lior ViderDirector3,6491.00%Jul 13, 2026
Liat SidiDirector3,6491.00%Jul 13, 2026
Amnon Ben ShayDirector3,6491.00%Jul 13, 2026
Moshe RevachDirector3,6491.00%Jul 13, 2026
Itschak ShremDirector11,0583.03%Jul 13, 2026
Alon DayanDirector3,6491.00%Jul 13, 2026
Amitay WeissDirector11,0583.03%Jul 13, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Itschak Shrem
Director
Jun 1, 2026Sale−462$10.00$4.62K10,596

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
James Edmond Smith
10% Stockholder
Jun 22, 202673,909$583.88KJun 22, 2026Open Market Purchase
Revach Moshe
DIRECTOR
Aug 21, 2023108,185$19.47KAug 17, 2023AT THE MARKET